
From “Super Skeptical” Beginnings, a New Immune-Modulatory Vaccine Awaits Phase 3 Results
Data exploring a new type of tumor-fighting vaccine, presented last week at the American Association for Cancer Research (AACR), hint at game-changing news that could come by the end of the year. IO Biotech, a developer of first-in-class immune modulating …